Part:BBa_K1011000:Design
ftsZ gene from E. coli on pSB1C3
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 322
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
There is an illegal EcoR1 restriction site at bp 102-107 of the gene. We changed the C at site 107 to a T, which maintained the codon optimization and removed the illegal restriction site.
Source
The organism for which we based our sequence is Escherichia coli str. K-12 substr. MG1655, located at the following NCBI url:
http://www.ncbi.nlm.nih.gov/nuccore/NC_000913.2?report=genbank&from=105305&to=106456
References
The European CanCer Organisation (ECCO). (2012, November 7). First trial in humans of 'minicells': A completely new way of delivering anti-cancer drugs. Science Daily, Retrieved from http://www.sciencedaily.com/releases/2012/11/121108181443.htm
Flemming, A. (2007). Minicells deliver lethal load to tumours. Nature Reviews Drug Discovery, 6, 519. doi: 10.1038/nrd2366.
Giacalone, M. J. et al. (2007). Immunization with non-replicating e. coli minicells delivering both protein antigen and dna protects mice from lethal challenge with lymphocytic choriomeningitis virus. Vaccine,25(12), 2279-2287. doi: 10.1016/j.vaccine.2006.11.069.
MacDiarmid, J. A., & Brahmbhatt, H. (2011). Minicells: Versatile vectors for targeted drug or si/shrna cancer therapy. Current Opinion in Biotechnology, 22, 909-916. doi: 10.1016/j.copbio.2011.04.008
MacDiarmid, J. A. et al. (2009). Sequential treatment of drug-resistant tumors with targetedminicells containing sirna or a cytotoxic drug. Nature Biotechnology,27(7), 643-654. doi: 10.1038/nbt.1547.
MacDiarmid, J. A. et al. (2007). Bacterial derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell, 11, 431-445. doi: 10.1016/j.ccr.2007.03.012.
Ward, J. E., & Lutkenhaus, J. (1985). Overproduction of ftsz induces minicell formation in e. coli. Cell, 42, 941-949. doi: 10.1016/0092-8674(85)90290-9.